MarketCap
Facebook
X
Telegram
Globus Medical Revenue | GMED
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Globus Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.94 B | 2.52 B | 1.57 B | 1.02 B | 958 M | 789 M | 785 M | 713 M | 636 M | 564 M | 545 M | 474 M | 434 M | 386 M | 331 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.94 B | 331 M | 978 M |
Quarterly Revenue Globus Medical
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 790 M | 760 M | 769 M | 745 M | 598 M | 626 M | 630 M | 607 M | 384 M | 292 M | 277 M | - | 254 M | 264 M | 231 M | - | 230 M | 251 M | 227 M | 233 M | 216 M | 149 M | 191 M | 212 M | 196 M | 195 M | 183 M | 196 M | 169 M | 173 M | 174 M | 176 M | 152 M | 152 M | 156 M | 152 M | 136 M | 137 M | 139 M | 143 M | 137 M | 134 M | 132 M | 129 M | 118 M | 114 M | 114 M | 115 M | 107 M | 107 M | 105 M | 101 M | 94.8 M | 96 M | 94.7 M | 88 M | 84.3 M | 80.9 M | 78.3 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 790 M | 78.3 M | 238 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Nemaura Medical
NMRD
|
77 K | - | -17.8 % | $ 2.74 M |  Britain |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M |  USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.64 B | $ 12.07 | 1.34 % | $ 925 M | USA |
 |
InMode Ltd.
INMD
|
370 M | $ 13.77 | -1.43 % | $ 890 M |  Israel |
 |
Apyx Medical Corporation
APYX
|
52.8 M | $ 2.41 | 1.69 % | $ 99 M | USA |
 |
Accuray Incorporated
ARAY
|
402 M | $ 0.12 | -4.69 % | $ 14.7 M | USA |
 |
IRadimed Corporation
IRMD
|
83.8 M | $ 85.76 | -0.12 % | $ 1.09 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.85 B | $ 126.54 | -0.01 % | $ 4.4 B | USA |
 |
Inogen
INGN
|
349 M | $ 7.05 | -0.77 % | $ 188 M | USA |
 |
Bruker Corporation
BRKR
|
3.44 B | $ 57.98 | 0.68 % | $ 8.8 B | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 45.24 | -0.91 % | $ 67 B | USA |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 79.76 | -1.41 % | $ 4.35 B | Britain |
 |
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.96 | 7.1 % | $ 79.7 M | USA |
 |
Medtronic PLC
MDT
|
36.4 B | $ 94.3 | -1.14 % | $ 121 B | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 4.26 | -19.26 % | $ 265 M | USA |
 |
Myomo
MYO
|
40.9 M | $ 1.2 | -1.64 % | $ 50.2 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
13 M | $ 0.35 | -4.75 % | $ 22.7 M | Israel |
 |
InspireMD
NSPR
|
8.98 M | $ 0.47 | 3.69 % | $ 30.2 M | Israel |
 |
Outset Medical
OM
|
119 M | $ 4.07 | -0.85 % | $ 61.9 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
PAVmed
PAVM
|
71 K | $ 2.26 | 4.15 % | $ 1.52 M | USA |
 |
Penumbra
PEN
|
1.4 B | $ 324.88 | 0.05 % | $ 12.6 B | USA |
 |
Insulet Corporation
PODD
|
2.71 B | $ 147.21 | -1.21 % | $ 10.4 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
AVITA Medical
RCEL
|
71.6 M | $ 15.23 | -1.8 % | $ 424 M |  Australia |
 |
Inspire Medical Systems
INSP
|
912 M | $ 70.62 | -0.58 % | $ 2.07 B | USA |
 |
Sintx Technologies
SINT
|
1.02 M | $ 1.61 | 1.9 % | $ 4.47 M | USA |
 |
Smith & Nephew plc
SNN
|
4.56 B | $ 30.4 | -1.43 % | $ 26.4 B | Britain |
 |
LENSAR
LNSR
|
58.4 M | $ 5.99 | -1.4 % | $ 71.6 M | USA |
 |
Sensus Healthcare
SRTS
|
27.5 M | $ 2.83 | -4.55 % | $ 46.2 M | USA |
 |
Stryker Corporation
SYK
|
7.17 B | $ 303.8 | -1.15 % | $ 116 B | USA |
 |
Tactile Systems Technology
TCMD
|
330 M | $ 23.65 | 0.08 % | $ 541 M | USA |
 |
TELA Bio
TELA
|
80.3 M | $ 1.01 | 4.66 % | $ 47.4 M | USA |
 |
Tandem Diabetes Care
TNDM
|
290 M | $ 18.23 | 4.59 % | $ 1.24 B | USA |
 |
Profound Medical Corp.
PROF
|
16.1 M | $ 5.55 | -0.14 % | $ 168 M | Canada |
 |
Viemed Healthcare
VMD
|
270 M | $ 9.7 | -1.02 % | $ 377 M | USA |
 |
Varex Imaging Corporation
VREX
|
845 M | $ 18.42 | -0.03 % | $ 763 M | USA |
 |
Quanterix Corporation
QTRX
|
139 M | $ 2.84 | -0.66 % | $ 121 M | USA |
 |
Vivos Therapeutics
VVOS
|
17.4 M | $ 0.13 | -2.84 % | $ 1.34 M | USA |
 |
Beyond Air
XAIR
|
7.68 M | $ 2.2 | 5.26 % | $ 18.3 B | USA |
 |
Xtant Medical Holdings
XTNT
|
134 M | $ 0.29 | 1.31 % | $ 40.5 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
8.23 B | $ 96.52 | -2.08 % | $ 19.1 B | USA |
 |
Align Technology
ALGN
|
4.03 B | $ 151.34 | -2.05 % | $ 11 B | USA |
 |
Abbott Laboratories
ABT
|
44.3 B | $ 104.05 | 0.35 % | $ 181 B | USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 5.91 | -1.91 % | $ 799 M | USA |
 |
Alphatec Holdings
ATEC
|
764 M | $ 10.96 | -1.4 % | $ 1.64 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |